Sanofi: appointment of Jean-Paul Kress

(CercleFinance.com) - The Board of Directors of Sanofi announces the appointment of Jean-Paul Kress as an independent director with effect from January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024.


Jean-Paul Kress will serve for the remainder of Gilles Schnepp's term, and his appointment will be subject to ratification at Sanofi's next Annual General Meeting.

Jean-Paul Kress served as Chief Executive Officer of MorphoSys from 2019 until its acquisition by Novartis in 2024.

Previously, Jean-Paul Kress was Chief Executive Officer of Syntimmune, a company focused on advanced clinical development in autoimmune diseases, until its acquisition by Alexion.

He has also held a number of management positions in other pharmaceutical companies in the USA and Europe.

Copyright (c) 2024 CercleFinance.com. All rights reserved.